StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV)

Investment analysts at StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report issued on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reduced their target price on Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th.

Minerva Neurosciences Trading Up 7.3 %

NERV opened at $2.95 on Friday. Minerva Neurosciences has a 12 month low of $2.26 and a 12 month high of $13.49. The company has a market cap of $20.62 million, a PE ratio of -0.66 and a beta of 0.14. The company has a 50 day moving average of $2.92 and a 200 day moving average of $2.79.

Minerva Neurosciences (NASDAQ:NERV) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.12). Research analysts forecast that Minerva Neurosciences will post -2.26 earnings per share for the current fiscal year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.